Table 3.

Treatment-emergent adverse events ≥10% (all grades, either arm) in patients with leiomyosarcoma

TEAE category, n (%)	Eribulin (n = 156)			Dacarbazine (n = 152)
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
Neutropenia	72 (46)	36 (23)	25 (16)	40 (26)	16 (11)	8 (5)
Fatigue	71 (46)	6 (4)	0	63 (41)	3 (2)	0
Nausea	64 (41)	1 (1)	0	74 (49)	1 (1)	0
Alopecia	51 (33)	1 (1)	0	5 (3)	0	0
Constipation	51 (33)	2 (1)	0	41 (27)	1 (1)	0
Anaemia	49 (31)	10 (6)	2 (1)	44 (29)	15 (10)	4 (3)
Pyrexia	46 (30)	2 (1)	0	20 (13)	0	0
Asthenia	35 (22)	2 (1)	0	34 (22)	4 (3)	0
Cough	34 (22)	0	0	24 (16)	0	0
Headache	32 (21)	0	0	17 (11)	0	0
Peripheral sensory neuropathy	30 (19)	2 (1)	0	6 (4)	0	0
Vomiting	30 (19)	2 (1)	0	34 (22)	0	0
Abdominal pain	28 (18)	3 (2)	1 (1)	21 (14)	6 (4)	0
Decreased appetite	27 (17)	1 (1)	0	21 (14)	0	0
Dyspnoea	27 (17)	3 (2)	1 (1)	25 (16)	3 (2)	2 (1)
Back pain	26 (17)	2 (1)	0	23 (15)	3 (2)	0
Diarrhoea	25 (16)	0	0	22 (15)	0	0
Leukopenia	25 (16)	12 (8)	4 (3)	20 (13)	5 (3)	3 (2)
Stomatitis	22 (14)	2 (1)	0	4 (3)	1 (1)	0
Oedema peripheral	21 (14)	0	0	11 (7)	1 (1)	0
Abdominal pain, upper	17 (11)	0	0	8 (5)	1 (1)	0
Hypokalemia	17 (11)	4 (3)	0	7 (5)	2 (1)	0
Aspartate aminotransferase increased	16 (10)	1 (1)	0	5 (3)	2 (1)	0
Myalgia	16 (10)	0	0	16 (11)	0	0
Urinary tract infection	16 (10)	2 (1)	0	10 (7)	0	0
Thrombocytopenia	10 (6)	1 (1)	0	47 (31)	13 (9)	13 (9)

TEAE treatment-emergent adverse event